Fred Alger Management’s Theravance Biopharma TBPH Stock Holding History

Fred Alger Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-19,000	Closed	-$689K	–	521
2016 Q3	$689K	Buy	19,000 +5,000	+36%	+$139K	﹤0.01%	336
2016 Q2	$318K	Buy	+14,000	New	+$302K	﹤0.01%	401
2015 Q4	–	Sell	-31,600	Closed	-$347K	–	589
2015 Q3	$347K	Buy	31,600 +8,700	+38%	+$111K	﹤0.01%	453
2015 Q2	$298K	Buy	+22,900	New	+$355K	﹤0.01%	488

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fred Alger Management's TBPH Position: Q4 2016 in Review

Fred Alger Management sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 19,000 shares — an estimated $689K sold.

Fred Alger Management first reported a position in TBPH in Q2 2015 and held it in 4 quarters. The position peaked at $689K in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

Fred Alger Management reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
Fred Alger Management sold 19,000 Theravance Biopharma shares in Q4 2016, an estimated $689K.
Fred Alger Management first reported a position in Theravance Biopharma in Q2 2015 and held it in 4 quarters.
Fred Alger Management's Theravance Biopharma position peaked at $689K in Q3 2016.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Fred Alger Management's 13F filing for Q4 2016, filed 14 Feb 2017.